Quick Takeaways
- BALYASNY ASSET MANAGEMENT L.P. filed SCHEDULE 13G for Contineum Therapeutics, Inc. Class A Common Stock, par value $0.001 per share (CTNM).
- Disclosed ownership: 7.6%.
- Date of event: 31 Dec 2025.
Quoteable Key Fact
"BALYASNY ASSET MANAGEMENT L.P. disclosed 7.6% ownership in Contineum Therapeutics, Inc. Class A Common Stock, par value $0.001 per share (CTNM) on 31 Dec 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Balyasny Asset Management L.P. | 7.6% | 2,312,800 | 0 | 2,312,800 | /s/ Scott Schroeder | Scott Schroeder / Authorized Signatory | |
| BAM GP LLC | 7.6% | 2,312,800 | 2,312,800 | 0 | /s/ Scott Schroeder | Scott Schroeder / Authorized Signatory | |
| Balyasny Asset Management Holdings LP | 7.6% | 2,312,800 | 2,312,800 | 0 | /s/ Scott Schroeder | Scott Schroeder / Authorized Signatory | |
| Dames GP LLC | 7.6% | 2,312,800 | 2,312,800 | 0 | /s/ Scott Schroeder | Scott Schroeder / Authorized Signatory | |
| Dmitry Balyasny | 7.6% | 2,312,800 | 2,312,800 | 0 | /s/ Dmitry Balyasny | Dmitry Balyasny / Self |